Comorbidities of hypothyroidism.

IF 2.2 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL Current Medical Research and Opinion Pub Date : 2025-03-01 Epub Date: 2025-03-12 DOI:10.1080/03007995.2025.2476075
Gabriela Brenta, Ulrike Gottwald-Hostalek
{"title":"Comorbidities of hypothyroidism.","authors":"Gabriela Brenta, Ulrike Gottwald-Hostalek","doi":"10.1080/03007995.2025.2476075","DOIUrl":null,"url":null,"abstract":"<p><p>Hypothyroidism is a relatively common condition that may affect as many as 10% of the population worldwide when its overt and subclinical presentations are considered. Important clinical comorbidities are highly prevalent in people with hypothyroidism and diminish quality of life and functional status in a manner that is proportional to the number of comorbidities present and their severity. This article reviews the common comorbidities of hypothyroidism, as reported in the literature. The comorbidities of hypothyroidism include clinical conditions commonly associated with hypothyroidism, such as dyslipidaemia, hypertension, fatigue or (possibly) cardiovascular disease, and can appear whether or not intervention with LT4 is applied appropriately to ensure biochemical euthyroidism. Other comorbidities may share some pathogenetic background with hypothyroidism, including depression or anxiety, or autoimmune conditions. Hypothyroidism may arise as a comorbidity of some other conditions, e.g. following the application of targeted cancer therapies or some disease-modfying treatments for multiple sclerosis. Other common treatments, including metformin, glucocorticoids or proton pump inhibitors, among others, may alter levels of thyrotropin, thus impacting on the monitoring of thyroid dysfunction and the diagnosis of thyroid dysfunction. Ensuring good control of hypothyroidism is a necessary first step in managing any patient with hypothyroidism. Then, physicians should be aware of the possibility of other comorbid conditions that must be addressed to achieve an optimal patient outcome.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"421-429"},"PeriodicalIF":2.2000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Medical Research and Opinion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/03007995.2025.2476075","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Hypothyroidism is a relatively common condition that may affect as many as 10% of the population worldwide when its overt and subclinical presentations are considered. Important clinical comorbidities are highly prevalent in people with hypothyroidism and diminish quality of life and functional status in a manner that is proportional to the number of comorbidities present and their severity. This article reviews the common comorbidities of hypothyroidism, as reported in the literature. The comorbidities of hypothyroidism include clinical conditions commonly associated with hypothyroidism, such as dyslipidaemia, hypertension, fatigue or (possibly) cardiovascular disease, and can appear whether or not intervention with LT4 is applied appropriately to ensure biochemical euthyroidism. Other comorbidities may share some pathogenetic background with hypothyroidism, including depression or anxiety, or autoimmune conditions. Hypothyroidism may arise as a comorbidity of some other conditions, e.g. following the application of targeted cancer therapies or some disease-modfying treatments for multiple sclerosis. Other common treatments, including metformin, glucocorticoids or proton pump inhibitors, among others, may alter levels of thyrotropin, thus impacting on the monitoring of thyroid dysfunction and the diagnosis of thyroid dysfunction. Ensuring good control of hypothyroidism is a necessary first step in managing any patient with hypothyroidism. Then, physicians should be aware of the possibility of other comorbid conditions that must be addressed to achieve an optimal patient outcome.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
甲状腺功能减退的合并症。
甲状腺功能减退症是一种相对常见的疾病,如果考虑到其显性和亚临床表现,全球可能有多达10%的人口患有这种疾病。重要的临床并发症在甲状腺功能减退症患者中非常普遍,这些并发症会降低患者的生活质量和功能状态,其程度与并发症的数量和严重程度成正比。本文回顾了文献报道中常见的甲减合并症。甲减的合并症包括与甲减常见的临床症状,如血脂异常、高血压、疲劳或(可能)心血管疾病,无论是否适当使用LT4进行干预以确保生化甲状腺功能正常,这些合并症都可能出现。其他合并症可能与甲状腺功能减退症有一些共同的发病背景,包括抑郁、焦虑或自身免疫性疾病。甲减可能是某些其他疾病的合并症,例如在应用癌症靶向疗法或阿利珠单抗治疗多发性硬化症之后。其他常见的治疗方法,包括二甲双胍、糖皮质激素或质子泵抑制剂等,可能会改变促甲状腺素的水平,从而影响甲状腺功能障碍的监测和诊断。确保甲状腺功能减退症得到良好控制是管理任何甲状腺功能减退症患者的第一步。然后,医生应意识到患者可能存在其他合并症,而这些合并症必须得到解决,以实现患者的最佳治疗效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current Medical Research and Opinion
Current Medical Research and Opinion 医学-医学:内科
CiteScore
4.40
自引率
4.30%
发文量
247
审稿时长
3-8 weeks
期刊介绍: Current Medical Research and Opinion is a MEDLINE-indexed, peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, Phase II-IV studies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged. Preclinical, Phase I, pharmacoeconomic, outcomes and quality of life studies may also be considered if there is clear clinical relevance
期刊最新文献
Observational design provides valuable representation of patient experience that complements controlled clinical trials: a response to the letter to the editor for "Health care provider- and patient-reported outcomes for bictegravir/emtricitabine/tenofovir alafenamide versus other antiretroviral regimens: an observational survey in the United States (July 2021-March 2022)". Experiences with real-world teclistamab administration in community and outpatient settings: a mixed-methods study of hematology providers. Integration of ımmunotherapy in limited-stage small cell lung cancer: a review of the literature. Heterogeneous comparators and unadjusted differences may bias PRO comparisons of B/F/TAF: a letter to editor in response to "Health care provider- and patient-reported outcomes for bictegravir/emtricitabine/tenofovir alafenamide versus other antiretroviral regimens: an observational survey in the United States". Effects of an exercise-based program on neutrophil-lymphocyte ratio and glycemic control in individuals with young-onset diabetes: a randomized controlled trial.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1